Keytruda Wave 1 | LaunchTrends | US | 2015
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).
LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity of Keytruda.
Related Market Assessment Reports
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
Report
Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (US)
Male hypogonadism (low testosterone, or low T) is a condition characterized by impaired spermatogenesis and low serum testosterone. Most cases are secondary, driven by aging or comorbidities (e.g…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
